Montreal / April 21, 2023 - NexPlasmaGen announces that it has received $511,186 in funding from the ministère de l'économie, de l'innovation et...
NEXPLASMAGEN TO PRESENT AT THE 2023 OBIO INVESTMENT SUMMIT Canada’s Premier Health Science Investment Event! Montreal/February 2, 2022 – NexPlasmaGen is proud to announce that...
Montreal / July 4, 2022 NexPlasmaGen is a finalist for the ADRIQ Innovation Award 2022 in the category Innovation from Public Research. The Innovation...
Montreal/June 23, 2022 – NexPlasmaGen is honored to present at the MedInvest Oncology Investor Conference. The MedInvest Oncology Investor Conference will be hosted in...
NEXPLASMAGEN TO PRESENT AT THE 2022 OBIO INVESTMENT SUMMIT Canada’s Premier Health Science Investment Event! Montreal/January 30, 2022 – NexPlasmaGen is proud to announce that...
NEXPLASMAGEN TO PRESENT AT SEED SHOWCASE 2022 NexPlasmaGen will pitch its business opportunity to investors! Montreal/December 24 – NexPlasmaGen, today announced that it is presenting...
NexPlasmaGen is proud to announce that the preclinical trials program led by Dr. Philip Wong at the Centre Hospitaller de l’Université de Montréal...
NexPlasmaGen Inc. is pleased to announce that its patented cold plasma technology is in preparation for clinical investigation for the treatment of breast...
NexPlasmaGen Inc. is pleased to announce the completion of $795,000 in private and public investment from individuals, Aligo Innovation, the Quebec MEDTEQ program...